GeoVax Announces Multiple Patent Issuances and Allowances
13 Febrero 2024 - 8:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, today announced multiple
actions by global patent offices strengthening the Company’s
intellectual property assets.
- The Japanese Patent Office issued a Decision of Grant notifying
GeoVax of the allowance of the Company’s Patent Application No.
2022-153352 titled “Compositions and Methods for Generating an
Immune Response to a Tumor Associated Antigen.” The allowed claims
are directed to recombinant MVA viral vectors comprising specific
MUC-1 nucleic sequences used in GeoVax’s MUC-1 tumor-associated
antigen immunotherapy program. Pharmaceutical compositions for
inducing immune responses, preventing or reducing neoplasm growth,
or treating cancer are also covered by the granted claims.
- The U.S. Patent and Trademark Office issued Patent No.
11,896,657 to GeoVax, pursuant to the Company’s patent application
No. 17/584,231 titled “Replication-Deficient Modified Vaccinia
Ankara (MVA) Expressing Marburg Virus Glycoprotein (GP) and Matrix
Protein (VP40).” The allowed claims generally cover GeoVax’s vector
platform for expressing Marburg virus antigens in virus-like
particles (VLPs) utilizing an MVA viral vector.
- The U.S. Patent and Trademark Office issued Patent No.
11,897,919 pursuant to the Company’s patent application No.
17/409,574 titled “Multivalent HIV Vaccine Boost Compositions and
Methods of Use.” The allowed claims generally cover a priming
vaccination with a DNA vector encoding multiple HIV antigens in
virus-like particles (VLPs), followed by a boost vaccination with
GeoVax’s vector platform for expressing HIV-1 antigens in VLPs
utilizing an MVA viral vector.
David Dodd, GeoVax President and CEO, commented, “These patent
actions add to our growing portfolio of wholly owned, co-owned, and
in-licensed intellectual property, now standing at over 115 granted
or pending patent applications spread over 24 patent families. Our
development priorities continue to be our next-generation Covid-19
vaccine, currently in Phase 2 clinical trials, and our cancer
immunotherapy program, with Gedeptin® as our lead product in a
Phase 1/2 clinical trial for advanced head and neck cancer. Beyond
these two programs, we continue to investigate MVA as a cancer
immunotherapy platform, as it has shown interesting potential to
address multiple cancer indications.”
Mr. Dodd continued, “Although not currently under active
development, our HIV program forms an important part of the dataset
underpinning all of our MVA-based development programs. The patent
protection associated with this vaccine is an important part of
this technology platform. Also, our team is committed to supporting
the successful advancement of vaccines against lethal hemorrhagic
fever viruses such as Marburg virus, as we recognize the critically
important medical and biodefense need, reflected by the inclusion
of Marburg virus in the FDA Priority Review Voucher program.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel therapies and vaccines for solid tumor cancers and
many of the world’s most threatening infectious diseases. The
company’s lead program in oncology is a novel oncolytic solid tumor
gene-directed therapy, Gedeptin®, presently in a multicenter Phase
1/2 clinical trial for advanced head and neck cancers. GeoVax’s
lead infectious disease candidate is GEO-CM04S1, a next-generation
COVID-19 vaccine targeting high-risk immunocompromised patient
populations. Currently in three Phase 2 clinical trials, GEO-CM04S1
is being evaluated as a primary vaccine for immunocompromised
patients such as those suffering from hematologic cancers and other
patient populations for whom the current authorized COVID-19
vaccines are insufficient, and as a booster vaccine in patients
with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is
in a Phase 2 clinical trial evaluating the vaccine as a more
robust, durable COVID-19 booster among healthy patients who
previously received the mRNA vaccines. GeoVax has a leadership team
who have driven significant value creation across multiple life
science companies over the past several decades. For more
information, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding
GeoVax’s business plans. The words “believe,” “look forward to,”
“may,” “estimate,” “continue,” “anticipate,” “intend,” “should,”
“plan,” “could,” “target,” “potential,” “is likely,” “will,”
“expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventative vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventative vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventative vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventative vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is contained in our
periodic reports on Form 10-Q and Form 10-K that we have filed and
will file with the SEC. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
Company Contact: |
|
Investor Relations Contact: |
|
Media Contact: |
info@geovax.com |
|
paige.kelly@sternir.com |
|
sr@roberts-communications.com |
678-384-7220 |
|
212-698-8699 |
|
202-779-0929 |
|
|
|
|
|
GeoVax Labs (NASDAQ:GOVXW)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
GeoVax Labs (NASDAQ:GOVXW)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024